Kailera Therapeutics, Inc. (NasdaqGS: KLRA)
Health Care · Biotechnology · US
$11.79
-3.36% today · -54.7% 1Y
Kailera Therapeutics, Inc. (NasdaqGS: KLRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.53B and employs 145 people.
Over the last twelve months the share price has lost 54.7%, trading between 9.76 and 28.23.
Tweenvest scores Kailera Therapeutics, Inc. across four factors: quality 57/100, value 100/100. Its strongest factor is value.
KLRA price history
Key figures
- Market cap
- $1.53B
- Revenue (TTM)
- —
- P/E
- -10.28
- EPS
- -7,819.98
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $28.23
- 52-week low
- $9.76
- Avg volume (3M)
- —
- Shares outstanding
- 129.85M
- Employees
- 145
- Next earnings
- —
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
- ISIN
- US4829311020
- Founded
- 2024
- Listed since
- Apr 17, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sarepta Therapeutics, Inc.NasdaqGS: SRPT | $1.56B | $14.17 | -2.48% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $1.54B | CN¥19.89 | -3.82% |
| Mesoblast LimitedASX: MSB | $1.53B | AU$1.76 | -1.95% |
| Vitrolife AB (publ)OM: VITR | $1.53B | Skr117.40 | -0.25% |
| TLC BioSciences Corp.TPEX: 7924 | $1.52B | NT$375.00 | -2.47% |
| Zhuhai Trinomab Pharmaceutical Co., Ltd.SHSE: 688806 | $1.52B | CN¥21.97 | -5.02% |
| Voronoi, Inc.KOSDAQ: A310210 | $1.51B | ₩111,000.00 | +1.19% |
| CanSino Biologics Inc.SEHK: 6185 | $1.50B | HK$23.34 | -1.85% |